Dimensions of response to antidepressant agents in bulimia nervosa: a review.

Many patients suffering from bulimia nervosa benefit from treatment with antidepressant medication. Nurses, like other mental health clinicians, tend to assess the effectiveness of a pharmacologic agent in patients with bulimia nervosa by the decline in the frequency of binge eating episodes. Clinical descriptions and research reports suggest the possibility of additional behavioral dimensions of treatment responsiveness, although the extent to which associated behaviors or symptoms improve is not well documented. This paper examines 16 placebo-controlled pharmacological trials in patients with bulimia nervosa to evaluate a range of potential measures of response to antidepressant intervention.

[1]  S. Specker,et al.  A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. , 1993, The International journal of eating disorders.

[2]  M. Gladis,et al.  Long-term outcome of antidepressant treatment for bulimia nervosa. , 1991, The American journal of psychiatry.

[3]  H G Pope,et al.  A placebo-controlled study of trazodone in bulimia nervosa. , 1989, Journal of clinical psychopharmacology.

[4]  M. Gladis,et al.  Bulimia and Depression , 1985, Psychosomatic medicine.

[5]  J. Mitchell,et al.  A Placebo‐Controlled, Double‐Blind Trial of Amitriptyline in Bulimia , 1984, Journal of clinical psychopharmacology.

[6]  M. Weissman,et al.  Assessment of social adjustment by patient self-report. , 1976, Archives of general psychiatry.

[7]  J. A. Schneider,et al.  Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. , 1992, The American journal of psychiatry.

[8]  T. Bushnik,et al.  Treatment of bulimia with fenfluramine and desipramine. , 1988, Journal of clinical psychopharmacology.

[9]  J. Treasure,et al.  A controlled study of alexithymia in eating disorders. , 1993, Comprehensive psychiatry.

[10]  S. Kennedy,et al.  Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. , 1993, Journal of clinical psychopharmacology.

[11]  S. Kennedy,et al.  Affective Disturbance in Eating Disorders , 1985, The Journal of nervous and mental disease.

[12]  D. Franko,et al.  Alexithymia ratings in bulimia nervosa: clinical correlates. , 1994, Psychosomatic medicine.

[13]  H G Pope,et al.  Bulimia treated with imipramine: a placebo-controlled, double-blind study. , 1983, The American journal of psychiatry.

[14]  R. Michels,et al.  Diagnostic and Statistical Manual of Mental Disorders, 3rd ed , 1981 .

[15]  J M Ferguson,et al.  Treatment of bulimia with bupropion: a multicenter controlled trial. , 1988, The Journal of clinical psychiatry.

[16]  J. Blouin,et al.  Treatment of Bulimia with Desipramine: A Double-Blind Crossover Study , 1988, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[17]  D. Ilstrup,et al.  Treating bulimia with desipramine. A double-blind, placebo-controlled study. , 1986, Archives of general psychiatry.

[18]  D. Herzog,et al.  A 3-year outcome study of normal-weight bulimia: Assessment of psychosocial functioning and eating attitudes , 1986, Psychiatry Research.

[19]  D. Hatsukami,et al.  A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. , 1990, Archives of general psychiatry.

[20]  M. Drake.  Diagnostic and Statistical Manual of Mental Disorders (3rd ed. rev.) , 1988 .

[21]  K. H. Barratt,et al.  Bulimia nervosa: a placebo controlled double-blind therapeutic trial of mianserin. , 1983, British journal of clinical pharmacology.

[22]  D. Goldbloom,et al.  Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. , 1993, The American journal of psychiatry.

[23]  S. Kennedy,et al.  A trial of isocarboxazid in the treatment of bulimia nervosa. , 1988, Journal of clinical psychopharmacology.

[24]  W. Stewart Agras,et al.  Imipramine in the treatment of bulimia: A double‐blind controlled study , 1987 .

[25]  Dc Washington.  Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[26]  T. Heatherton,et al.  Development and validation of a scale for measuring state self-esteem. , 1991 .

[27]  E Brunner,et al.  Fluoxetine Versus Placebo: A Double-Blind Study with Bulimic Inpatients Undergoing Intensive Psychotherapy , 1991, Pharmacopsychiatry.

[28]  H. Steiger,et al.  Psychopathological features in bulimics as a function of axis‐II comorbidity: Isolation of mood‐independent differences , 1992 .

[29]  T. Brewerton,et al.  Alexithymia in the eating disorders. , 1993, The International journal of eating disorders.

[30]  James I. Hudson,et al.  Phenomenologic relationship of eating disorders to major affective disorder , 1983, Psychiatry Research.

[31]  A. Brotman,et al.  Pharmacologic Approaches in the Treatment of Eating Disorders , 1993, Harvard review of psychiatry.

[32]  A H Glassman,et al.  Phenelzine vs placebo in 50 patients with bulimia. , 1988, Archives of general psychiatry.